Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $31.18.
CAI has been the topic of a number of research analyst reports. Canaccord Genuity Group lifted their target price on Caris Life Sciences from $22.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Citigroup upped their target price on Caris Life Sciences from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, November 6th. BTIG Research restated a “buy” rating and set a $38.00 price target on shares of Caris Life Sciences in a research note on Thursday, November 5th. UBS Group set a $38.00 price target on Caris Life Sciences in a research note on Thursday, November 5th. Finally, Weiss Ratings raised Caris Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, November 9th.
View Our Latest Report on Caris Life Sciences
Caris Life Sciences Trading Down 2.2%
CAI opened at $19.50 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.84 and a current ratio of 6.71. Caris Life Sciences has a one year low of $14.19 and a one year high of $36.50. The company has a market cap of $5.59 billion, a P/E ratio of 60.42, a PEG ratio of 6.50 and a beta of 0.71. The business’s 50-day simple moving average is $29.12 and its 200-day simple moving average is $21.63.
Caris Life Sciences (NASDAQ:CAI – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a return on equity of 16.00% and a net margin of 9.16%. The firm had revenue of $275.36 million during the quarter. During the same quarter in the previous year, the firm earned $0.08 EPS. Caris Life Sciences’s revenue for the quarter was up 27.0% compared to the same quarter last year. As a group, equities research analysts expect that Caris Life Sciences will post 0.11 EPS for the current fiscal year.
Insider Activity
In other news, insider John Russel Denton sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total transaction of $238,650.00. Following the transaction, the insider directly owned 174,855 shares in the company, valued at approximately $5,563,886.10. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President David Spetzler sold 119,212 shares of Caris Life Sciences stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.76, for a total transaction of $2,951,689.12. Following the completion of the transaction, the president directly owned 1,182,871 shares in the company, valued at $29,287,885.96. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 1,004,712 shares of company stock valued at $27,205,419. 50.00% of the stock is currently owned by company insiders.
Institutional Trading of Caris Life Sciences
A number of hedge funds have recently added to or reduced their stakes in CAI. GAMMA Investing LLC grew its position in Caris Life Sciences by 133.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock valued at $39,000 after buying an additional 721 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after buying an additional 1,469 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of Caris Life Sciences in the 1st quarter worth $31,000. Root Financial Partners LLC acquired a new stake in shares of Caris Life Sciences in the 3rd quarter worth $60,000. Finally, MCF Advisors LLC purchased a new stake in shares of Caris Life Sciences in the second quarter valued at about $36,000.
About Caris Life Sciences
Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.
Further Reading
- Five stocks we like better than Caris Life Sciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
